Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
HOME > TOP STORIES
TOP STORIES
-
ACADEMIA Experts, Industry Execs Say Cost Calculation Drug Pricing Method Fraught with Challenges
September 8, 2015
-
ORGANIZATION Drug Pricing Tomorrow: Full Interview with FPMAJ’s Kamoya - Part 2
September 8, 2015
-
REGULATORY MHLW Announces Comprehensive Strategy to Beef Up Pharma Industry, Vows to Promote Reward for Innovation
September 7, 2015
-
REGULATORY MEXT Funding Research Project to Propose New Business Models and Financing Methods to Promote Drug Development
September 4, 2015
-
BUSINESS Merck Serono Japan Wants to Be Leader in Oncology, Fertility: President
September 3, 2015
-
BUSINESS Pfizer Japan Slapped with Biz Improvement Order over ADR Reporting
September 2, 2015
-
ORGANIZATION Cost-Effective Assessment Must Not Delay Patient Access: PhRMA’s HTA Chief
September 1, 2015
-
ACADEMIA ASCO Immunotherapy Roundup - 9: Researcher Says Predominance of Anti-PD-1 Antibodies Not Assured
September 1, 2015
-
BUSINESS Towa Raises Production Target to 14 Billion Tablets: Pres. Yoshida
August 31, 2015
-
REGULATORY Panel OKs Medical Subsidy for Harvoni, Monthly Copay Up to 20,000 Yen
August 28, 2015
-
REGULATORY Chuikyo Reps Trade Barbs over Pricing of Harvoni, Listing OK'ed by a Whisker
August 27, 2015
-
REGULATORY Chuikyo OKs Listing of Harvoni, Peak Sales Put at 119 Billion Yen in 2nd Year
August 26, 2015
-
REGULATORY MHLW Reveals Outline of “Comprehensive Strategy” for Pharma Sector
August 25, 2015
-
BUSINESS ASCO Immunotherapy Roundup - 8: 5 Immune Checkpoint Inhibitors Projected to Rake in 2 Trillion Yen in 2020
August 25, 2015
-
REGULATORY Drug Pricing Tomorrow: MHLW Councilor Takeda Says NHI Drug Prices Should Mirror Evaluation of Individual Firms
August 24, 2015
-
REGULATORY Council on “Clinical Innovation Network” Holds 1st Meeting, 7 Working Groups to Design Registries
August 21, 2015
-
REGULATORY MHLW to Seek FY2016 Budgets for Genomic Data Collection, Registry-Based Trial Platform
August 20, 2015
-
ORGANIZATION Drug Pricing Tomorrow: Full Interview with FPMAJ’s Kamoya - Part 1
August 20, 2015
-
BUSINESS Rheumatism Specialty Firm Ayumi Eyes Sales of 40-60 Billion Yen in 10 Years
August 19, 2015
-
BUSINESS Sawai’s Evista Generic Approved after Patent Battle
August 18, 2015
ページ
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
Takeda Pharmaceutical’s overseas sales ratio has reached 90.9%, exceeding 90% for the first time though only in the first half…
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
A Japanese health ministry panel on November 28 agreed on a plan to legally require pharma companies to set up…
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…